US Stock Insider Trading | Veracyte Discloses 5 Insider Transactions on March 2

On March 2, 2026, Veracyte (VCYT) disclosed five insider transactions. Director Stapley Marc sold 35,800 shares on February 26, 2026.

[Recent Insider Transactions]

[Company Information]

Veracyte, Inc., a subsidiary of Calderome Holdings, was incorporated in Delaware on August 15, 2006.

Until early 2008, Calderome operated as a startup incubator. On March 4, 2008, the company was renamed Veracyte Ltd. Veracyte is a pioneering diagnostic company in the field of molecular cytology, aiming to improve patient outcomes and reduce healthcare costs. The company specializes in providing accurate diagnoses for diseases that often require invasive procedures—many healthy patients undergo costly interventions that are ultimately unnecessary. The company collects clinically actionable genomic information from outpatient cytology specimens, improving diagnostic accuracy early in patient care. Its first commercial solution, Afirma Thyroid FNA Analysis, includes its core gene expression classifier (GEC). GEC helps physicians reduce unnecessary surgeries by using proprietary 142-gene markers to preoperatively determine whether thyroid nodules, previously classified as indeterminate by cytopathology, can be reclassified as benign. The company’s headquarters are located in South San Francisco, California, and Austin, Texas, and it operates within a single department.